Sign In
Buy CGEM
$16.50
-1.02 (-5.82%)
At Close: Jul 31, 2026
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clini
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
07:00am, Tuesday, 16'th Apr 2024
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
06:59am, Tuesday, 16'th Apr 2024
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Thursday, 14'th Mar 2024
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies
Cullinan Oncology to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 27'th Feb 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapie
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:53pm, Monday, 18'th Dec 2023
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therap
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07:00am, Wednesday, 08'th Nov 2023
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
12:01pm, Friday, 03'rd Nov 2023
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed
Cullinan Oncology to Participate in Upcoming Investor Conferences
08:00am, Monday, 30'th Oct 2023
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapie
Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data
11:57am, Monday, 11'th Sep 2023
Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EG
Cullinan Oncology to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapi
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
07:00am, Thursday, 10'th Aug 2023
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment
CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that
